<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488239</url>
  </required_header>
  <id_info>
    <org_study_id>Rally-CRT-P-02-2015</org_study_id>
    <nct_id>NCT02488239</nct_id>
  </id_info>
  <brief_title>Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)</brief_title>
  <acronym>Rally CRT-P</acronym>
  <official_title>Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Post Market Clinical Follow-up (PMCF) is to collect data on the
      performance of the Ingenio 2 CRT-P devices and to document that device-related events, device
      malfunctions or device deficiencies (DDs) do not increase safety risks in Ingenio 2 CRT-P
      devices (CRT-Ps), both in general and specific to the new features and hardware of the
      devices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, non-randomized, multi-center, single group, post market clinical study The
      devices are fully commercially available and all subjects are planned to receive a CRT-P
      implant as part of their standard of care (SOC). The assignment of the specific Ingenio 2
      device is physician's choice and will consider leads currently in place from previous devices
      and planned new leads (e.g., Acuity X4 and/or other LV leads).

      Enrollment and Consenting Clinic Visit (≤ 30 days prior to implant procedure) (required)

        -  Implant Procedure (Day 0; all future follow ups based on this date) (required)

        -  Pre-Discharge Clinic Visit (after pocket closure and wound coverage 0-5 days
           post-implant procedure) (required)

        -  1 month post-implant Clinic Visit (30 ± 15 days) (required)

        -  3 month post-implant Clinic Visit (91 ± 21 days) (required)

        -  Latitude-based Close-out (91 - 120 days months post last enrollment) (reporting only
           required)

        -  Unscheduled clinic follow-up (any clinic visit between pre-discharge and 3 month follow
           up which is in addition to the 1 month follow up; per center SOC or subject needs; event
           reporting only)

        -  Re-implant/Revision (as needed)

        -  During the trial unanticipated serious adverse device effects (USADEs), serious adverse
           device effects (SADEs), adverse device effects (ADEs), DDs, all serious adverse events
           (SAEs), deaths, and changes in the device system must be reported (enrollment to
           Closeout).

      Study Duration Enrollment is expected to take 12 months. The study will be considered
      complete (primary endpoint completion) after all subjects have completed the Latitude based
      close-out 3-4 months after the last study enrollment. All study required visits will be
      completed as part of regularly scheduled clinic visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Without CRT-P Device Related Complications</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>Evaluate the Device-Related Complication Free Rate (DRCFR) at 3 months post-implant, which was based on complications that were related to the CRT-P device. A device-related complication was an adverse event that resulted in death, serious injury, a correction using invasive intervention or permanent loss of device functions, and that was assessed as related to the device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LV Pacing Threshold</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>Primary Effectiveness endpoint: evaluation of the left ventricular pacing threshold measurements performed at 0.5 ms pulse width at 3 months post-implant.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Post Market Surveillance Study Following Clinical Routine</condition>
  <arm_group>
    <arm_group_label>CRT-P indicated patients</arm_group_label>
    <description>Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-P indicated patients</intervention_name>
    <description>Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device</description>
    <arm_group_label>CRT-P indicated patients</arm_group_label>
    <other_name>Pacemaker implant</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Planned to be implanted or replaced with a VISIONIST Ingenio 2 CRT-P device

        The Ingenio 2 CRT-Ps are indicated for patients who have symptomatic congestive heart
        failure (CHF) including left ventricular (LV) dysfunction and wide QRS, and/or one or more
        of the following conditions:

        Symptomatic paroxysmal or permanent second- or third-degree atrioventricular (AV) block
        Symptomatic bilateral bundle branch block Symptomatic paroxysmal or transient sinus node
        dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia,
        sinus arrest, sinoatrial [SA] block) Bradycardia-tachycardia syndrome, to prevent
        symptomatic bradycardia or some forms of symptomatic tachyarrhythmias Neurovascular
        (vaso-vagal) syndromes or hypersensitive carotid sinus syndromes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years or above, or above legal age to give informed consent specific to state and
             national law

          2. Willing and capable of providing informed consent

          3. Planned to be implanted or replaced with a VISIONIST Ingenio 2 CRT-P device

          4. Planned to be implanted with a 3-lead CRT-P system

          5. Planned to be connected to the remote data collection through the Latitude® system

          6. Able to do a 6 minute walk test

          7. Maximum sensor rate of age predicted maximal heart rate (APMHR) 80% should be
             clinically acceptable

          8. Willing and capable of participating in all visits associated with this study at an
             approved clinical study center and at the intervals defined-

        Exclusion Criteria:

          1. Documented life expectancy of less than 12 months

          2. Currently on the active heart transplant list

          3. Enrolled in any other concurrent study without prior written approval from Boston
             Scientific, with the exception of local mandatory governmental registries and
             observational studies/registries that are not in conflict and do not affect the
             following:

               -  Schedule of procedures for the Rally CRT-P Study (i.e., should not cause
                  additional or missed visits)

               -  Rally CRT-P Study outcomes (i.e., involve medications that could affect the heart
                  rate of the subject)

               -  Conduct of the Rally CRT-P Study per Good Clinical Practice (GCP)/ International
                  Standard Organization (ISO) 14155:2011/ local regulations as applicable

          4. In chronic atrial fibrillation

          5. APMHR needs to be programmed &lt; 80%.

          6. Not planned to receive a functional atrial lead

          7. Per the implanting physician's discretion, subject is not a suitable candidate to
             receive the study device as determined during the implant procedure

          8. Women of childbearing potential who are or might be pregnant at the time of study
             enrollment

          9. Unwilling or unable to participate in all scheduled study follow up visits at an
             approved study center

         10. Does not anticipate being a resident of the area for the scheduled duration of the
             trial. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Pakarinen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Gefäßzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Landshut-Achdorf</name>
      <address>
        <city>Landshut</city>
        <zip>84036</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harzklinikum Quedlinburg</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <results_first_submitted>August 14, 2018</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02488239/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 11 May 2015 and the study was completed on 22 March 2017, which corresponds to the last visit of the last subject. A total of 64 subjects across 8 centers were enrolled in Finland and Germany.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Actively Enrolled Patients</title>
          <description>Patients actively enrolled and implanted with a 3-lead CRT-P system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not undergo implant procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Actively Enrolled Patients</title>
          <description>Patients actively enrolled and implanted with a 3-lead CRT-P system.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Without CRT-P Device Related Complications</title>
        <description>Evaluate the Device-Related Complication Free Rate (DRCFR) at 3 months post-implant, which was based on complications that were related to the CRT-P device. A device-related complication was an adverse event that resulted in death, serious injury, a correction using invasive intervention or permanent loss of device functions, and that was assessed as related to the device.</description>
        <time_frame>3 months post-implant</time_frame>
        <population>Out of 61 actively enrolled subjects (3 subjects were not implanted with the study device), 55 patients continued the study for at least 3 months: 6 subjects were excluded from analysis because either they died or withdrew before 3 months analysis, or because no 3 months data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Actively Enrolled Patients</title>
            <description>Subjects actively enrolled and implanted with a 3-lead CRT-P system.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Without CRT-P Device Related Complications</title>
          <description>Evaluate the Device-Related Complication Free Rate (DRCFR) at 3 months post-implant, which was based on complications that were related to the CRT-P device. A device-related complication was an adverse event that resulted in death, serious injury, a correction using invasive intervention or permanent loss of device functions, and that was assessed as related to the device.</description>
          <population>Out of 61 actively enrolled subjects (3 subjects were not implanted with the study device), 55 patients continued the study for at least 3 months: 6 subjects were excluded from analysis because either they died or withdrew before 3 months analysis, or because no 3 months data was available.</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>exact binomial rate</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LV Pacing Threshold</title>
        <description>Primary Effectiveness endpoint: evaluation of the left ventricular pacing threshold measurements performed at 0.5 ms pulse width at 3 months post-implant.</description>
        <time_frame>3 months post-implant</time_frame>
        <population>61 actively enrolled subjects were included in the analysis. 3 subjects did not receive the study device.</population>
        <group_list>
          <group group_id="O1">
            <title>Actively Enrolled Patients</title>
            <description>Patients actively enrolled and implanted with a 3-lead CRT-P system.</description>
          </group>
        </group_list>
        <measure>
          <title>LV Pacing Threshold</title>
          <description>Primary Effectiveness endpoint: evaluation of the left ventricular pacing threshold measurements performed at 0.5 ms pulse width at 3 months post-implant.</description>
          <population>61 actively enrolled subjects were included in the analysis. 3 subjects did not receive the study device.</population>
          <units>Volt</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.38" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from enrollment throughout study completion (last subject last visit)</time_frame>
      <desc>All adverse events are collected as per ISO 14155:2011 and medical device guidance (MEDDEV) 2.7/3 12/2010</desc>
      <group_list>
        <group group_id="E1">
          <title>Actively Enrolled Patients</title>
          <description>Patients actively enrolled and implanted with a 3-lead CRT-P system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Other SVT</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pulmonary edema - heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Heart failure symptoms - unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chest pain - ischemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Mitral regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>LV - elevated threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>LV - extracardiac stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>RA - dislogement - elevated threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>RV - dislodgement - elevated threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Procedure - coronary venous dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspnea - Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Other- Patient condition - Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Premature atrial contractions (PAC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Premature ventricular contractions (PVC)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Head, eyes, ears, nose, throat (HEENT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Other- Patient condition - Non- cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Elevated threshold - RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation - LV</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Inability to maintain telemetry</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Infection (&gt; 30 days post-implant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Other - Lead - Procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pacemaker-mediated tachycardia (PMT)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Undersensing - RA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma - Pocket (&lt;= 30 days post-implant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Pneumothorax - Procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 30 days from the time submitted to the sponsor for review. The sponsor can request changes to the communication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Beaudoint</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>+32479904163</phone>
      <email>Caroline.Beaudoint@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

